News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dyax Corp. (DYAX) And ICOS Corporation (ICOS) Enter Into License Agreement For Discovery Of Therapeutic Antibodies



5/22/2006 12:33:48 PM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 22, 2006--Dyax Corp. (Nasdaq: DYAX - News) announced today that it has granted a non-exclusive license to its proprietary phage display libraries to ICOS Corporation (Nasdaq: ICOS - News) for the discovery and development of therapeutic antibodies. Under the terms of the agreement, Dyax receives technology license fees from ICOS, as well as clinical milestone payments and royalties on net sales of any products that may result from ICOS's use of the Dyax libraries. The agreement provides ICOS with a license to Dyax's antibody phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.

Read at press release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES